NASDAQ:PTIX - Nasdaq - US74365N2027 - Common Stock - Currency: USD
0.257
-0.03 (-10.73%)
The current stock price of PTIX is 0.257 USD. In the past month the price increased by 2.8%. In the past year, price decreased by -80.08%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 16.96 | 303.70B | ||
AMGN | AMGEN INC | 14.26 | 151.96B | ||
GILD | GILEAD SCIENCES INC | 22.75 | 130.75B | ||
VRTX | VERTEX PHARMACEUTICALS INC | 1675.48 | 124.91B | ||
REGN | REGENERON PHARMACEUTICALS | 12.04 | 60.05B | ||
ARGX | ARGENX SE - ADR | 314.22 | 35.70B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 29.98B | ||
ONC | BEIGENE LTD-ADR | N/A | 24.58B | ||
BNTX | BIONTECH SE-ADR | N/A | 23.62B | ||
NTRA | NATERA INC | N/A | 20.30B | ||
SMMT | SUMMIT THERAPEUTICS INC | N/A | 17.00B | ||
BIIB | BIOGEN INC | 7 | 16.87B |
Protagenic Therapeutics, Inc. operates as a biotechnology company. The company is headquartered in New York City, New York and currently employs 1 full-time employees. Its lead compound, PT00114, is a synthetic form of Teneurin Carboxy-terminal Associated Peptide (TCAP), an endogenous brain signaling peptide that can dampen overactive stress responses. Its lead compound is a 41-amino-acid synthetic peptide, which focuses on treating various neuro-psychiatric conditions, including depression, anxiety, and post-traumatic stress disorder (PTSD). The company operates with a novel mechanism, mirroring the active part of the natural brain hormone TCAP, thereby reducing circulating cortisol levels. In addition, it has a portfolio of earlier stage neuropeptides targeting the TCAP pathway that are in preclinical evaluation. The initial dosage form is intended as a subcutaneous injection but is also amenable to other routes of administration including sublingually or intra-nasally.
PROTAGENIC THERAPEUTICS INC
149 Fifth Avenue, Suite 500
New York City NEW YORK 10010 US
CEO: Garo H. Armen
Employees: 2
Company Website: https://protagenic.com/
Investor Relations: https://protagenic.com/investor/sec-filings/
Phone: 12129948200
The current stock price of PTIX is 0.257 USD. The price decreased by -10.73% in the last trading session.
The exchange symbol of PROTAGENIC THERAPEUTICS INC is PTIX and it is listed on the Nasdaq exchange.
PTIX stock is listed on the Nasdaq exchange.
PROTAGENIC THERAPEUTICS INC (PTIX) has a market capitalization of 1.94M USD. This makes PTIX a Nano Cap stock.
PROTAGENIC THERAPEUTICS INC (PTIX) currently has 2 employees.
PROTAGENIC THERAPEUTICS INC (PTIX) has a resistance level at 0.38. Check the full technical report for a detailed analysis of PTIX support and resistance levels.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
PTIX does not pay a dividend.
PROTAGENIC THERAPEUTICS INC (PTIX) will report earnings on 2025-05-13.
PROTAGENIC THERAPEUTICS INC (PTIX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.14).
The outstanding short interest for PROTAGENIC THERAPEUTICS INC (PTIX) is 1.86% of its float. Check the ownership tab for more information on the PTIX short interest.
ChartMill assigns a technical rating of 1 / 10 to PTIX. When comparing the yearly performance of all stocks, PTIX is a bad performer in the overall market: 95.19% of all stocks are doing better.
ChartMill assigns a fundamental rating of 1 / 10 to PTIX. The financial health of PTIX is average, but there are quite some concerns on its profitability.
Over the last trailing twelve months PTIX reported a non-GAAP Earnings per Share(EPS) of -1.14. The EPS increased by 0.96% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -282.49% | ||
ROE | -545.33% | ||
Debt/Equity | 0 |
ChartMill assigns a Buy % Consensus number of 83% to PTIX. The Buy consensus is the average rating of analysts ratings from 7 analysts.